William Blair analyst Sami Corwin maintains $Neurogene (NGNE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 50.8% and a total average return of 4.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
Preliminary NGN-401 Phase 1/2 data appear to surpass the efficacy benchmarks, demonstrating what seems to be a genuine clinical improvement in 4 pediatric Rett patients. The most significant concern may revolve around the 'emerging SAE' observed at the high dose of NGN-401 and the potential implications for the program's risk profile. Notably, the efficacy of NGN-401 to date is observed at the lower dose, which has seemingly exhibited a relative safety.
The company's Phase 1/2 readout has been recognized as a validation of NGN-401 in Rett syndrome, demonstrating unprecedented and potentially approvable efficacy, coupled with favorable safety at a lower dose. Nonetheless, investor attention has been drawn to uncertainty surrounding a treatment-related serious adverse event in the high dose cohort.
The sentiment towards Neurogene's shares is positive following the announcement of initial interim clinical data for its gene therapy NGN-401 in Rett syndrome. It is believed that the efficacy data is, more likely than not, sufficient to back its approval.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
威廉博莱分析师Sami Corwin维持$Neurogene (NGNE.US)$买入评级。
根据TipRanks数据显示，该分析师近一年总胜率为50.8%，总平均回报率为4.1%。
此外，综合报道，$Neurogene (NGNE.US)$近期主要分析师观点如下：
NGN-401 1/2 期初步数据似乎超过了疗效基准，这表明 4 名儿科 Rett 患者的临床状况似乎得到了真正的改善。最重要的担忧可能围绕在高剂量 NGN-401 下观察到的 “新兴SAE” 及其对该计划风险状况的潜在影响。值得注意的是，迄今为止，NGN-401 的疗效是在较低的剂量下观察到的，这似乎表现出相对的安全性。
该公司的1/2期读数被公认为对雷特综合征中 NGN-401 的验证，显示出前所未有且可能获得批准的疗效，同时在较低剂量下具有良好的安全性。尽管如此，围绕高剂量队列中与治疗相关的严重不良事件的不确定性引起了投资者的注意。
在宣布其治疗雷特综合征的基因疗法 NGN-401 的初步中期临床数据后，人们对Neurogene股票的情绪乐观。据信，疗效数据很可能足以支持其批准。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
